Abelcet Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Funding
• Alerts
• Clinical Trials

Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia
Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia Intervention:   Drug: Oral Encochleated Amphotericin B (CAMB) Sponsors:   Matinas BioPharma Nanotechnologies, Inc.;   University of Cologne;   The Clinical Trials Centre Cologne Not yet recruiting - verified June 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 31, 2017 Category: Research Source Type: clinical trials

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
Conditions:   Vulvovaginal Candidiases;   Yeast Infection;   Vulvovaginitis;   Yeast Infection Vaginal;   Candidiasis, Vulvovaginal Interventions:   Drug: Oral Encochleated Amphotericin B (CAMB);   Drug: Oral Encochleated Amphotericin B (CAMB) Sponsor:   Matinas BioPharma Nanotechnologies, Inc. Not yet recruiting - verified May 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 23, 2017 Category: Research Source Type: clinical trials